CA2528182A1 - Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees - Google Patents

Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees Download PDF

Info

Publication number
CA2528182A1
CA2528182A1 CA002528182A CA2528182A CA2528182A1 CA 2528182 A1 CA2528182 A1 CA 2528182A1 CA 002528182 A CA002528182 A CA 002528182A CA 2528182 A CA2528182 A CA 2528182A CA 2528182 A1 CA2528182 A1 CA 2528182A1
Authority
CA
Canada
Prior art keywords
antibody
seq
human
variable region
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002528182A
Other languages
English (en)
Inventor
Jing Ma
Yajun Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomax Acquisition Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB2003101199264A external-priority patent/CN1279056C/zh
Application filed by Individual filed Critical Individual
Publication of CA2528182A1 publication Critical patent/CA2528182A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002528182A 2003-06-06 2004-06-04 Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees Abandoned CA2528182A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN03129123 2003-06-06
CN03129123.6 2003-06-06
CNB2003101199264A CN1279056C (zh) 2003-06-06 2003-11-25 肿瘤相关抗原sm5－1的特异性抗体及其应用
CN2003101199264 2003-11-25
US10/722,849 US20050031617A1 (en) 2003-06-06 2003-11-26 Antibodies specific for cancer associated antigen SM5-1 and uses thereof
US10/722,849 2003-11-26
TW092133571A TW200517122A (en) 2003-06-06 2003-11-28 Antibodies specific for cancer associated antigen SM5-1 and uses thereof
TW092133571 2003-11-28
PCT/US2004/017855 WO2005053604A2 (fr) 2003-06-06 2004-06-04 Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees

Publications (1)

Publication Number Publication Date
CA2528182A1 true CA2528182A1 (fr) 2005-06-16

Family

ID=42331655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002528182A Abandoned CA2528182A1 (fr) 2003-06-06 2004-06-04 Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees

Country Status (5)

Country Link
JP (1) JP2007535905A (fr)
AU (1) AU2004294893A1 (fr)
CA (1) CA2528182A1 (fr)
IL (1) IL172242A0 (fr)
WO (1) WO2005053604A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB2429013C (en) 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) * 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (fr) 2007-10-05 2018-05-16 Genentech, Inc. Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
EP2558494B1 (fr) 2010-04-15 2018-05-23 AbbVie Inc. Protéines de liaison à la bêta amyloïde
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
RU2556816C1 (ru) * 2014-03-12 2015-07-20 Открытое акционерное общество "Фармацевтический импорт, экспорт" (ОАО "Фармимэкс") Штамм клеток яичников китайского хомячка - продуцент рекомбинантного антитела против фактора некроза опухоли альфа человека
CN109627337B (zh) * 2018-12-29 2023-07-21 上海复宏汉霖生物技术股份有限公司 一种抗prlr的单克隆抗体及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
AU2004294893A1 (en) 2005-06-16
WO2005053604A2 (fr) 2005-06-16
IL172242A0 (en) 2006-04-10
WO2005053604A3 (fr) 2006-02-09
JP2007535905A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
US11174323B2 (en) Method of treating renal cancer using carbonic anhydrase IX (G250) antibodies
JP7592022B2 (ja) 抗クローディン１８．２抗体及びその用途
CA2600505C (fr) Anticorps diriges contre la mesotheline
MXPA04004857A (es) ANTICUERPOS DE COLáGENA HUMANIZADOS Y METODOS RELACIONADOS.
AU2004294893A1 (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
US20030198638A1 (en) Tumor specific monoclonal antibodies
CA2737597A1 (fr) Anticorps entierement humains diriges contre un antigene associe au melanome de masse moleculaire elevee et leurs utilisations
US20050031617A1 (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
IL317725A (en) An antibody targeting ITGA2 and a drug conjugate antibody containing it
NZ736924A (en) Igf-1r antibody and its use for the diagnosis of cancer
NZ577824A (en) Methods of identifying neoplasm-specific antibodies and uses thereof
WO2023103962A1 (fr) Molécule de liaison à tnfr2 et son utilisation
US20050232926A1 (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2004020574A2 (fr) Fragment scfv en rapport avec la cathepsine l humaine et leurs procedes d'utilisation
CA2467020A1 (fr) Anticorps monoclonaux specifiques de tumeur
EP4722245A1 (fr) Anticorps ciblant itga2, conjugué anticorps-médicament correspondant, et utilisation
AU2009305715B8 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
HK40060501B (en) Anti-claudin 18.2 antibody and application thereof

Legal Events

Date Code Title Description
FZDE Discontinued